ArticleFrontiers in molecular neuroscience2021
Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers.
Article in Frontiers in molecular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The Role of Hydrogen Sulfide (HInternational journal of molecular sciences · 2023Pooled it
- The Expanding Role of Non-Coding RNAs in Neurodegenerative Diseases: From Biomarkers to Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Designing RNA sequencing experiments: A practical guide to reproducible gene expression analysis.Computational and structural biotechnology journal · 2026Review
- Beyond the ends: potential implications of telomeric repeat-containing RNA (TERRA) for CNS diseases.Journal of molecular cell biology · 2025Review
- Molecular crosstalk between miRNAs and lncRNAs in neurodegenerative disease pathways.Molecular biology reports · 2025Review
- RNA sequencing of the lncRNA regulome modulated by Withania somnifera in human neuroblastoma SK-N-SH cells.Molecular biology reports · 2025Article
- Human Blood-Derived lncRNAs in Autism Spectrum Disorder.Biomolecules · 2025Review
- Noncoding RNAs and their influence on maternal mental health: insights into perinatal depression: a review.Molecular biology reports · 2025Review
- Novel insights into neuropathy: The impact of prolonged hyperglycemia on long non-coding RNA expression.PloS one · 2025Article
- A Glimpse of Noncoding RNAs: Secondary Structure, Emerging Trends, and Potential Applications in Human Diseases.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Unraveling the microRNAs Involved in Fasciolosis: Master Regulators of the Host-Parasite Crosstalk.International journal of molecular sciences · 2024Review
- Expression Profiling of Coding and Noncoding RNAs in the Endometrium of Patients with Endometriosis.International journal of molecular sciences · 2024Article
- Huntingtin is an RNA binding protein and participates inScience advances · 2024Article
- Non-Coding RNAs and Neurodegenerative Diseases: Information of their Roles in Apoptosis.Molecular neurobiology · 2024Review
- Brain-Periphery Interactions in Huntington's Disease: Mediators and Lifestyle Interventions.International journal of molecular sciences · 2024Review
- lncRNA Biomarkers of Glioblastoma Multiforme.Biomedicines · 2024Review
- The Potential of Targeting Autophagy-Related Non-coding RNAs in the Treatment of Alzheimer's and Parkinson's Diseases.Cellular and molecular neurobiology · 2024Review
- Role of long non-coding RNAs in the pathophysiology of Alzheimer's disease and other dementias.Molecular biology reports · 2024Review
- Noncoding RNAs in Alzheimer's Disease: Overview of Functional and Therapeutic Significance.Current topics in medicinal chemistry · 2024Review
- Scoping review of epigenetics on neurodegenerative diseases: research frontiers and publication status.Frontiers in neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are progressive and ultimately fatal. NDD onset is influenced by several factors including heredity and environmental cues. Long noncoding RNAs (lncRNAs) are a class of noncoding RNA molecules with: (i) lengths greater than 200 nucleotides, (ii) diverse biological functions, and (iii) highly conserved structures. They directly interact with molecules such as proteins and microRNAs and subsequently regulate the expression of their targets at the genetic, transcriptional, and post-transcriptional levels. Emerging studies indicate the important roles of lncRNAs in the progression of neurological diseases including NDDs. Additionally, improvements in detection technologies have enabled quantitative lncRNA detection and application to circulating fluids in clinical settings. Here, we review current research on lncRNAs in animal models and patients with NDDs. We also discuss the potential applicability of circulating lncRNAs as biomarkers in NDD diagnostics and prognostics. In the future, a better understanding of the roles of lncRNAs in NDDs will be essential to exploit these new therapeutic targets and improve noninvasive diagnostic methods for diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.